Dana-Farber Cancer Institute, Inc.

Dana-Farber Cancer Institute – Merrimack Valley nurses held a one-day strike seeking a fair contract and DFCI locked nurses out, spent money on replacement workers BOSTON, Sept. 28, 2023 /PRNewswire/ -- During a lockout inflicted on Merrimack Valley nurses and patients by Dana-Farber Cancer Institute (DFCI) following a one-day strike, nurses will meet outside the DFCI hospital in Boston on Friday, September 29 to leaflet the public and share their concerns about how Dana-Farber executives are spending critical resources. Boston DFCI Event Details Where: On the sidewalk outside Dana-Farber Cancer Institute in Boston along Jimmy Fund Way. When: 11 a.m. Friday, September 29 Who: Dana-Farber nurses from Boston and Merrimack Valley. What: Nurses will be sharing leaflets with the public describing what DFCI – MV nurses are seeking in a first MNA contract so they can continue providing high-quality cancer care to MV patients. DFCI – MV nurses and nurse practitioners held a one-day strike on September 27 because DFCI executives refused to make reasonable compromises with nurses to reach a fair contract. Instead of reaching a reasonable compromise with nurses, DFCI is refusing to let nurses back to work following the strike. DFCI executives are spending money on travelers rather than allowing local nurses to care for their patients. DFCI is disaffiliating from Brigham and Women's Hospital and spending millions on a new inpatient hospital. Yet it won't invest properly in nurses serving a diverse population in MV. DFCI – MV nurses have made compromises already and are seeking to secure Merrimack Valley-based benefits in their contract and pay that is competitive in Merrimack Valley and a reasonable difference from DFCI Boston pay. DFCI has made minimal movement since nurses announced their strike, including no agreement on maintaining benefits throughout the contract or daily overtime standards. "We are incredibly grateful for the support our community showed us during our one-day strike," said Kate Mitchell, FNP-BC, AOCNP at DFCI – MV. "Patients joined us on the strike line because we are fighting for their cancer care, and they deserve nurses who are truly valued." "Our strike showed that the Merrimack Valley community and our elected officials are behind us in our fight for a fair contract," said Kerrin Albert, Infusion RN at DFCI – MV. "Don't listen to Dana-Farber executives – we have compromised and made reasonable contract proposals. Dana-Farber has stubbornly insisted on giving us far less because we are not in Boston." "Dana-Farber makes huge profits and enriches its executives while Merrimack Valley nurses must strike and be locked out for fair benefits and wages," said Errin D'Arcangelo, Oncology Nurse Navigator at DFCI – MV. "We think Dana-Farber should spend its money – which comes from patients, donors, and the public – on respecting nurses and maintaining high-quality patient care." DFCI – MV nurses voted 97% to authorize a strike on August 2. DFCI – MV nurses held an informational picket on June 2. Among those in attendance supporting the nurses were State Senator Pavel Payano, D-Lawrence, and State Representative Ryan Hamilton, D-Methuen. "As you know, these healthcare professionals are on the front lines of caring for patients and liaising with families," Rep. Hamilton wrote in an August 2 letter to Dr. Laurie Glimcher, president, and CEO of Dana-Farber. "They play a vital role here in Merrimack Valley by supporting patients through the hardship of a cancer diagnosis and bolstering our fight against this disease." DFCI – Merrimack Valley opened in 2020 with 24 exam rooms and 32 infusion bays. The location offers expanded cancer and blood disorder care and outpatient services for adult patients in the region. DFCI – MV nurses voted in June and July 2022 to form a union and join the MNA. The MNA also represents approximately 600 nurses at the DFCI campus in Boston under a separate contract. Dana-Farber Financial Highlights DFCI made $110 million in profits (excess of revenue over expenses) during the fiscal quarter ending March 31, 2023, according to the Center for Health Information and Analysis. It made $87.5 million during the previous quarter. DFCI's total operating revenue for the first six months of FY2023 was approximately $1.5 billion, an increase of $196.9 million, or 15.7 percent, over the same period in 2022. Dr. Laurie Glimcher, president and CEO of Dana-Farber, saw a 15.4% increase in pay during the COVID-19 pandemic. The institute's IRS 990 form shows Glimcher made more than $2 million in total compensation during FY2021. MassNurses.org │ Facebook.com/MassNurses │ Twitter.com/MassNurses │ Instagram.com/MassNurses Founded in 1903, the Massachusetts Nurses Association is the largest union of registered nurses in the Commonwealth of Massachusetts. Its 25,000 members advance the nursing profession by fostering high standards of nursing practice, promoting the economic and general welfare of nurses in the workplace, projecting a positive and realistic view of nursing, and by lobbying the Legislature and regulatory agencies on health care issues affecting nurses and the public. SOURCE Massachusetts Nurses Association

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- More than 850 supporters came together during Ovarian Cancer Awareness Month to raise over $2.6MM for critical research at the Tina's Wish Gala on Thursday, September 21st at Pier Sixty in NYC. The event hosted by Emmy Award-winning Journalist and Two-time Ovarian Cancer Survivor, Joyce Kulhawik, celebrated the 15th Anniversary of the Foundation and honored Pachulski Stang Ziehl & Jones Partner, Laura Davis Jones, and Milbank Partner, Dennis Dunne, for their contributions to mentoring and leadership. Continue Reading Tina's Wish Gala Celebrates 15 Years and Raises $2.6MM for Ovarian Cancer Early Detection Research Tweet this Tina’s Wish Gala Celebrates 15 Years and Raises $2.6MM for Ovarian Cancer Early Detection Research "The diagnosis of ovarian cancer is scary and horrific, and the loss of life from ovarian cancer is unacceptable," said Davis Jones during her remarks. "I firmly believe that early detection is within our reach, and that goal will be achieved by the continued funding of the great research and outside-the-box thinking that is being done through Tina's Wish." Tina's Wish Scientific Advisory Board Co-Chair and Medical Oncologist at Dana-Farber Cancer Institute, Dr. Joyce Liu, reflected on milestones over the past fifteen years. "In these past 15 years, there have been continuous advances in science and technology that give us a better understanding of how ovarian cancers develop, and which offer new cutting-edge tools that may allow us to 'crack the nut' of ovarian cancer early detection," said Liu. "It's been a privilege to be part of Tina's Wish – they are a catalyst for collaborative research that will drive ovarian cancer early detection forward." Tina's Wish honors the memory of Tina Brozman, former chief judge of the U.S. Bankruptcy Court for the Southern District of New York, who died from ovarian cancer in 2007. Since its inception, Tina's Wish has raised over $24MM for research for the early detection and prevention of ovarian cancer. Most ovarian cancer patients are diagnosed at advanced stages due to the lack of an effective early detection method. Statistically, the five-year survival rate for women diagnosed at Stage III/IV is only 27%. The five-year survival rate for women diagnosed at Stage I is 92%, demonstrating that tools for early detection are critical. One of the evening's honorees, Dennis Dunne, ended his remarks with encouragement."We have the power to effectuate meaningful and lasting change through Tina's Wish," said Dunne. "We honor the memory of Tina Brozman and the countless women who are affected by ovarian cancer through our support for this cause." To see photos or make a donation, visit: tinaswish.org/gala23 Contact: Beverly Wolfer Executive Director Tina's Wish [email protected] SOURCE The Honorable Tina Brozman Foundation for Ovarian Cancer Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte’s global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte’s chief executive officer. This press release features multimedia. View the full release here: Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Photo: Business Wire) “Phil is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley. “His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world.” Dr. Febbo has more than 25 years of experience across academia and industry. He most recently served as chief medical officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers. Prior to that, he was chief medical officer for Genomic Health, where he oversaw the development and expansion of the company’s test portfolio, including the evidence demonstrating clinical validity and clinical utility in order to drive reimbursement. Before Genomic Health, Dr. Febbo was a professor of medicine and urology at the University of California, San Francisco Medical Center, and prior to that he was an associate professor of medicine and molecular genetics and microbiology at Duke University School of Medicine. He currently serves on the board of the Reagan Udall Foundation for the U.S. Food and Drug Administration (FDA). Dr. Febbo holds a B.A. in Biology from Dartmouth College and earned his M.D. from the University of California, San Francisco. He completed his internal medicine residency at Brigham and Women's Hospital and his medical oncology fellowship at the Dana Farber Cancer Institute. “Cancer mortality rates have started to improve due to better detection and management. Veracyte has distinguished itself with its high-performing tests that are helping physicians use underlying biology of an individual’s cancer to make personalized management decisions that improve patient outcomes and healthcare efficiencies,” said Dr. Febbo. “I am thrilled to join the company’s talented team and to help advance the future of insight-driven care.” About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit and follow the company on Twitter (@veracyte). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that Dr. Febbo will help advance novel tests that address important unmet patient-care needs in cancer. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at . These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.